Strattera (atomoxetine) is not a stimulant. It is the first non-stimulant medication approved by the FDA specifically for treating ADHD, and it is not classified as a controlled substance. This distinction matters for how it works in the brain, how quickly you’ll notice results, and whether it carries a risk of abuse.
How Strattera Works Differently Than Stimulants
Stimulant ADHD medications like Adderall and Ritalin work by boosting levels of both dopamine and norepinephrine throughout the brain. This produces a rapid, noticeable increase in focus and alertness, often within an hour of taking a dose. Strattera takes a different route. It selectively blocks the reabsorption of norepinephrine, a chemical messenger involved in attention, impulse control, and arousal. By keeping more norepinephrine available in the spaces between brain cells, it gradually improves ADHD symptoms over weeks rather than minutes.
Interestingly, Strattera does appear to boost dopamine signaling in the prefrontal cortex, the brain region most involved in planning, decision-making, and attention. Research published in the Proceedings of the National Academy of Sciences found that both Strattera and stimulants normalized the same underactive brain circuits in people with ADHD during attention tasks. So while the two drug classes take different pharmacological paths, they end up influencing some of the same brain networks.
No Abuse Potential or Controlled Substance Status
One of the biggest practical differences between Strattera and stimulants is the abuse question. Stimulants like methylphenidate and amphetamine are Schedule II controlled substances, meaning they have recognized medical use but also a high potential for dependence. Prescriptions often come with restrictions: no automatic refills, limits on how many days’ supply you can receive at once, and requirements for in-person visits.
Strattera carries none of these restrictions. In clinical studies comparing it to a placebo, it showed no pattern of stimulant-like or euphoric effects. You won’t feel a “kick” when you take it, which is precisely why it has no abuse potential and why refills are simpler to manage. For people with a history of substance use, or for parents concerned about a teenager misusing medication, this is often a deciding factor.
How Long Strattera Takes to Work
Because Strattera is not a stimulant, it doesn’t produce same-day results. Most people need 4 to 8 weeks at the right dose before they experience the full benefit. The typical starting dose for adults is 40 mg per day, increasing after a minimum of three days to a target of 80 mg. If that isn’t enough after another two to four weeks, the dose can go up to a maximum of 100 mg per day. For children and adolescents, dosing is based on body weight.
This slow ramp-up can be frustrating if you’re expecting the immediate clarity that stimulants provide. But it also means Strattera delivers steady, around-the-clock coverage without the peaks and valleys that some people experience with short-acting stimulants. There’s no “wearing off” in the afternoon and no rebound irritability in the evening.
Common Side Effects
Strattera’s side effect profile reflects its non-stimulant nature. In adults, the most common issues in clinical trials were dry mouth (21% vs. 6% on placebo), insomnia (16% vs. 8%), nausea (12% vs. 5%), decreased appetite (10% vs. 3%), and constipation (10% vs. 4%). Some adults also reported decreased libido (6%) and erectile difficulties (7% of men).
In children and adolescents, stomach-related side effects dominate. Upper abdominal pain affected 16 to 20% of kids in trials, vomiting hit 11 to 15%, and decreased appetite occurred in about 14%. Nausea, fatigue, and mood swings were also more common than with placebo. Many of these GI side effects improve after the first few weeks, and taking Strattera with food can help.
Effects on Heart Rate and Blood Pressure
Even though Strattera is not a stimulant, it does have mild cardiovascular effects because norepinephrine plays a role in heart function. On average, patients experience a heart rate increase of about 5 to 6 beats per minute and a blood pressure rise of less than 5 mmHg. For most people, these changes are too small to notice or cause problems.
However, roughly 6 to 12% of patients in clinical trials experienced more significant jumps: heart rate increases of 20 or more beats per minute, or blood pressure increases of 15 to 20 mmHg. People who process the drug more slowly due to genetic differences in liver enzymes may be more susceptible to these larger shifts. If you already have high blood pressure or a heart condition, these numbers are worth discussing with your prescriber before starting.
The Boxed Warning for Young People
Strattera carries an FDA boxed warning about suicidal thoughts in children and adolescents. In pooled data from 12 short-term trials involving over 2,200 young patients, 0.4% of those on Strattera experienced suicidal ideation compared to none on placebo. No suicides occurred in any of these trials. This risk appears highest early in treatment, so close monitoring during the first several weeks is standard. The warning applies specifically to children and adolescents, not adults.
Why Someone Might Choose Strattera Over a Stimulant
Strattera tends to be a good fit in specific situations. If stimulants cause intolerable side effects like severe anxiety, tics, or sleep disruption, Strattera offers a fundamentally different mechanism. If there’s a concern about substance misuse, its lack of abuse potential removes that worry entirely. And because it isn’t a controlled substance, managing prescriptions is less burdensome, with fewer pharmacy visits and no risk of running into supply shortages that periodically affect stimulant medications.
The tradeoff is that Strattera is generally considered less potent for core ADHD symptoms than stimulants. Many clinicians still use stimulants as a first-line option and turn to Strattera when stimulants aren’t a good match. Some people also use Strattera alongside a stimulant, with Strattera providing a baseline of coverage and a low-dose stimulant handling the rest. The right choice depends on your symptom severity, your medical history, and how you respond to each option individually.